Witold P.
- Country
- Poland
- Department
- Poliklinika Kardiologiczna Serce
Research Overview
- Efficacy and Safety of Orforglipron in Participants with Peripheral Artery Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
- A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization
- Effect of Muvalaplin on Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: A Phase 3 Randomized Trial
Data & Insights
Has run more than one trial at 47 of 469 partner sites.
Specializations
Atherosclerotic Cardiovascular Disease and lipid-related risk
Witold Piotrowski is involved in clinical research focused on atherosclerotic cardiovascular disease and the management of elevated lipoprotein(a), with attention to reducing major cardiovascular events and related ischemic complications.
- Major adverse cardiovascular events
- Lipoprotein(a)-driven cardiovascular risk
- Coronary and cerebrovascular event prevention
The research profile includes therapies aimed at lowering cardiovascular burden in adults with elevated lp(a) and established ASCVD.
Heart Failure with Obesity
His work also covers heart failure in the setting of obesity, including patients with HFpEF and HFmrEF, where the therapeutic focus is on reducing heart-failure-related clinical worsening and urgent care needs.
- HFpEF
- HFmrEF
- Heart failure hospitalisation
This area reflects interest in cardiovascular therapies that address both symptomatic heart failure and obesity-associated risk.
Obesity and metabolic cardiovascular risk
Witold Piotrowski is engaged in studies centered on obesity and overweight, with therapeutic attention to cardiometabolic outcomes, kidney-related complications, and broader risk reduction in patients living with excess body weight.
- Obesity
- Overweight
- Kidney outcomes
These investigations place weight-related disease within the context of cardiovascular and renal protection.
Peripheral Arterial Disease and walking impairment
His clinical trial activity includes peripheral arterial disease, with a therapeutic emphasis on improving functional capacity and walking performance in affected participants.
- Peripheral arterial disease
- Maximum walking distance
- Functional limitation
This area adds a vascular and mobility-focused dimension to the investigator’s cardiovascular research portfolio.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.